Erschienen in:
29.08.2019 | ASO Author Reflections
ASO Author Reflections: Effects of the Updated AJCC Classification for Patients with Stage III Melanoma
verfasst von:
Dimitrios Katsarelias, MD, Karolin Isaksson, MD, Roger Olofsson Bagge, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
The incidence of cutaneous melanoma is steadily increasing in most countries with fair-skin populations. According to the American Joint Committee on Cancer (AJCC) staging manual, patients with satellite/in-transit metastasis and/or regional lymph node disease are classified as stage III melanoma, which is further divided into subgroups according to prognosis. The AJCC 7th edition was recently replaced with the updated AJCC 8th edition, and the number of subgroups in stage III were revised from three (A–C) to four (A–D) groups.
1 The subgroup classification now depends on both T and N status, and the previous low-risk group (stage IIIA) has an even better prognosis, while patients with the highest risk are now classified as stage IIID. This substage migration can have an impact on the clinical management of patients with stage III melanoma. …
